Analysts Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) PT at $106.20

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has earned an average recommendation of “Hold” from the twenty-two research firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $106.20.

A number of equities research analysts have issued reports on ZBH shares. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday, January 26th. Robert W. Baird reissued a “neutral” rating and issued a $100.00 target price (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. UBS Group restated a “sell” rating and set a $89.00 target price on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 11th. Finally, Sanford C. Bernstein lifted their price target on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a report on Friday, January 9th.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZBH. Advisortrust Partners LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at approximately $442,000. Corient Private Wealth LLC increased its stake in Zimmer Biomet by 11.5% in the 4th quarter. Corient Private Wealth LLC now owns 46,989 shares of the medical equipment provider’s stock worth $4,230,000 after acquiring an additional 4,863 shares during the last quarter. Auto Owners Insurance Co raised its holdings in shares of Zimmer Biomet by 8,892.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock worth $180,713,000 after acquiring an additional 1,987,362 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of Zimmer Biomet by 4,020.2% during the 4th quarter. Pacer Advisors Inc. now owns 697,753 shares of the medical equipment provider’s stock valued at $62,742,000 after acquiring an additional 680,818 shares during the last quarter. Finally, Monetary Solutions Ltd bought a new position in shares of Zimmer Biomet during the 4th quarter valued at approximately $30,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $92.68 on Friday. The company has a market capitalization of $18.13 billion, a price-to-earnings ratio of 26.18, a PEG ratio of 1.92 and a beta of 0.58. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The stock’s 50-day simple moving average is $92.34 and its 200-day simple moving average is $95.38. Zimmer Biomet has a 52 week low of $84.59 and a 52 week high of $114.44.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm’s revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.